Oncolytics Biotech (ONCY) Operating Margin (2016 - 2017)
Oncolytics Biotech's (ONCY) quarterly Operating Margin came in at 765.44% in Q2 2017, down 113376.0% year-over-year from N/an in Q2 2016, and down 307.82% quarter-over-quarter from 368.32% in Q2 2016.
Powered by 
Analysis
Oncolytics Biotech (ONCY) Operating Margin (2016 - 2017) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Operating Margin for 2 consecutive years, with 765.44% the latest figure, recorded in Q2 2017.
- On a quarterly basis, Operating Margin fell 113376.0% year-over-year to 765.44% in Q2 2017; TTM through Jun 2017 was 52.99%, a 5406.0% increase from a year earlier, with the FY2020 full-year figure at 62.55%, changed N/A from the prior year.
- Operating Margin was 765.44% for Q2 2017 at Oncolytics Biotech, down from 368.32% in the prior quarter.
- Over five years, Operating Margin peaked at 368.32% in Q2 2016 and troughed at 765.44% in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | -25,380.93% |
| 10 | Oncolytics Biotech | 91.58 Mn | 91.58 Mn | - | - |